◆ DRXT18s02（iPS cells expressing the third highest HLA in Japan※1）

Clone ID	DRXT18s02	**Product**	Human iPS cells
Source	Peripheral Blood, Human	**Race**	Japanese
Passage No.	9	**Gender**	Male
Lot No.	20170709-13	**Manufacture Dates**	July 9th, 2017
Culture medium	StemFit AK03N	**Substrate**	iMatrix-511MG
Culture Method	Feeder-free (※2)		
Plasmids for reprograming	pCE-hSK, pCE-hUL, pCE-hOCT3/4, pCE-mp53DD, pCXB-EBNA1		
Use and Provision of this cell stock	Please visit our web site for details ; https://www.cira-foundation.or.jp/e/project/stock.html		

（※1）**Reference;** Okita, *et. al.*, Nat Methods. 2011 8(5): 409-412

（※2）**Reference;** Nakagawa, *et. al*., Nat Biotechnol. 2008 26(1):101-106

Test Result

Test	Method	Result
Sterility	BacT/ALERT	Negative
Mycoplasma	PCR	Negative
Endotoxin	LAL	≦ 5 EU/mL
Virus （HBV, HCV, HIV, HTLV, Parvovirus B19）	PCR	Negative
HLA typing （HLA-A, B, DR）	PCR-SBT	Consistent with the donor cells
STR genotyping	PCR	Consistent with the donor cells
Morphology	Microscope	Consistent with human ES cells
Karyotype	Conventional Giemsa analysis G-banding	46,XY[20]
Plasmid remnants	qPCR	Below the limit of quantification
CNV(※3)	CNV analysis	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.83) and Shibata list(※5) .
SNV/Indel(※4)	SNV/Indel(※3)	No de novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.83) and Shibata list(※5).
Undifferentiated markers	Microarray(※6)	*POU5F1*：4.8%、*NANOG*：6.7%（Relative expression levels of *GAPDH*）
	Flow cytometry (※6)	TRA-1-60: 95.2% SSEA4: 99.6% TRA-2-49: 99.6%

Thawed postnatal cells	Counting the number of the cells (※6, 7)	1.70×10^5 cells（Survival rate; 93.0%）
Number of proliferating cells after thawing	Counting the number of the cells after culturing for 7 days(※6, 7).	4.8×10^5 cells（Number of seeded cells; 1.63×10^5 cells）
Doubling time（h）	Counting the number of the cells (※6, 7)	P12→P13: 43.0 P13→P14: 28.4 P14→P15: 29.4 P15→P16: 27.0 P16→P17: 29.5

（※3）CNV; Copy Number Variation

（※4）SNV/Indel; Single nucleotide variants /Insertion Deletion

（※5）The PMDA Science Board “Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials”（Cellular- and Tissue-based Products Subcommittee, 20 August 2013）

（※6）ThermoFisher Countess®

（※7）The result of # 1 out of 3 frozen stocks is shown.

■Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)

CiRA Foundation